https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50584 Wed 28 Feb 2024 15:06:35 AEDT ]]> Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14877 Sat 24 Mar 2018 08:22:24 AEDT ]]> BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47367 Fri 13 Jan 2023 14:57:43 AEDT ]]>